Major trial seeks best chemo for seniors with blood cancer
NCT ID NCT07132684
Summary
This large study aims to find out which of two chemotherapy combinations works better for older adults (ages 55-75) with a serious blood cancer called acute myeloid leukemia (AML). Researchers will compare a newer drug combo (Venetoclax + Azacitidine) against a standard, more intensive combo (Daunorubicin/Idarubicin + Cytarabine) in 240 participants who are healthy enough for strong treatment. The main goal is to see which treatment helps patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.